Mitochondrial neurogastrointestinal encephalomyopathy: approaches to diagnosis and treatment

Area of Science:

• Genetics and Molecular Biology
• Neurology
• Gastroenterology

Background:

• Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) is an ultra-rare genetic disorder.
• Caused by mutations in the thymidine phosphorylase (TYMP) gene, leading to enzyme deficiency.
• Results in systemic accumulation of thymidine and 2'-deoxyuridine, causing mitochondrial DNA depletion and failure.

Purpose of the Study:

• To review current diagnosis and treatment approaches for MNGIE.
• To increase clinical awareness of MNGIE for earlier diagnosis.
• To facilitate timely access to treatments before irreversible organ damage.

Main Methods:

• Literature review of MNGIE diagnosis and treatment.
• Summary of clinical characteristics and pathophysiology.
• Discussion of therapeutic strategies targeting metabolic abnormalities.

Main Results:

• MNGIE presents with gastrointestinal dysmotility, cachexia, neuropathy, ophthalmoplegia, ptosis, and leukoencephalopathy.
• Progressive degenerative nature leads to premature death, averaging 37.6 years.
• Patients often face misdiagnosis and delayed management.

Conclusions:

• MNGIE is a treatable mitochondrial disorder due to its accessible molecular abnormality.
• Early diagnosis and intervention are critical for managing MNGIE.
• Increased clinical awareness can improve patient outcomes by enabling timely treatment.